Evaluation of the effectiveness and safety of bianshi moxibustion infrared dry eye therapeutic instrument in the treatment of meibomian gland dysfunction

Peking University Third Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Aged 18~80 years old;
•2. Diagnostic criteria of dry eye:
•(1) Ocular symptoms:
•1) Feeling dry eye every day for more than 3 months;
•2) Repeated foreign body sensation;
•3) Using artificial tears more than 3 times one day;
•(2) Ocular signs:
•1) Schirmer I test (ST-I)(no anesthesia) <=5mm / 5min;
•2) Corneal fluorescein staining score >=4 (according to van Bijsterveld scoring standard);
•The diagnosis of dry eye requires at least one symptom and one sign.
•3. Diagnostic criteria of meibomian gland dysfunction
•(1) Absence of meibomian glands;
•(2) Abnormal of eyelid margin and meibomian gland;
•(3) Changes in the quantity and quality of meibomian secretion;
•MGD could be diagnosed with any of these signs in combination with dry eye symptoms.

•(1) Caused by systemic diseases (pain, fever, cough) or other external environmental factors.
•(2) Complicated with other eye diseases (glaucoma, cataract, retinal detachment, etc.) or undergone eye surgery.
•(3) Systemic connective tissue disease or severe autoimmune diseases
•(4) Patients with central nervous system disease or craniocerebral surgery.
•(5) Patients with severe diseases of heart, lung, liver, kidney or blood system.
•(6) Patients who suspect or have a history of alcohol or drug abuse or mental illness.
•(7) Allergic constitution.
•(8) Pregnant or lactating women.
•(9) Patients who have taken medication for dry eye in the last 2 weeks.
•(10) Patients who have participated in other clinical trials within the last 1 month or have accepted the randomized group of this clinical trial.
•(11) The investigator considers that the participants are not suitable for this clinical trial.

发起方